ProKidney Expects Q2 2027 Phase 3 PROACT 1 Pivotal Trial Results for Rilparencel

ProKidney Corp reported a net loss of $151.61 million for FY2025, down from $163.34 million in the prior year. The company has $270 million in cash and expects it to fund operating expenses and capital expenditure requirements into mid-2027. ProKidney is developing Rilparencel, a cell therapy for chronic kidney disease, and plans to complete enrolment in its Phase 3 PROACT 1 study by mid-2026. The company expects to complete full enrolment and report topline results for accelerated approval in Q2 2027.